Related Experiment Videos
Eligibility for streptokinase thrombolysis during evolving acute myocardial infarction. An historical cohort study
1Department of Family Practice, Malcolm Grow USAF Medical Center, Andrews AFB, MD 20331.
Insights
Approximately one-third of acute myocardial infarction patients are eligible for streptokinase thrombolysis. This finding supports the continued use of traditional management strategies for acute myocardial infarction.
Area of Science:
- Cardiology
- Emergency Medicine
- Pharmacology
Background:
- Acute myocardial infarction (AMI) is a leading cause of mortality worldwide.
- Thrombolytic therapy, such as streptokinase, has been a cornerstone in managing AMI.
- Patient selection is crucial for optimizing thrombolytic therapy outcomes.
Purpose of the Study:
- To ascertain the proportion of AMI patients suitable for streptokinase thrombolysis.
- To evaluate the eligibility criteria for streptokinase administration in a real-world setting.
Main Methods:
- Retrospective chart review of 990 patients with a discharge diagnosis of AMI across four hospitals.
- Confirmation of AMI diagnosis using enzyme and electrocardiogram criteria.
- Assessment of patient suitability for streptokinase based on age (≤75 years), infarction type (transmural), absence of contraindications, and timely presentation (≤6 hours from symptom onset).
Main Results:
- Of 750 confirmed AMI cases, 233 patients (31%) met the criteria for streptokinase thrombolysis.
- Key eligibility factors included younger age, transmural infarction, no anticoagulation contraindications, and early hospital presentation.
Conclusions:
- Approximately one-third of AMI patients in this cohort were suitable candidates for streptokinase thrombolysis.
- These findings underscore the significant, ongoing role of traditional AMI management approaches alongside newer therapies.
Abstract:
To determine the percentage of acute myocardial infarction patients suitable for streptokinase thrombolysis, the charts of 990 patients from four separate hospitals with a discharge diagnosis of acute myocardial infarction were studied. In all, 750 were confirmed to actually have suffered acute myocardial infarction by enzyme and electrocardiogram criteria. Of these, 233 (31 percent of all patients with acute myocardial infarction) were judged to be suitable streptokinase candidates by virtue of being 75 years of age or younger, showing evidence of acute transmural infarction, having no contraindications to anticoagulation, and presenting to the Emergency Room within six hours or less after onset of chest pain. It is concluded that approximately one-third of all acute myocardial infarction patients in this population were eligible for streptokinase thrombolysis and that there is therefore a significant continuing role for traditional acute myocardial infarction management.